Background. Percutaneous coronary intervention using a drug-eluting stent (DES) is a common therapeutic option for acute coronary syndrome (ACS). However, stent-associated complications, such as bleeding associated with dual antiplatelet therapy, in-stent restenosis, stent thrombosis, and neoatherosclerosis, remain. Drug-coated balloons (DCBs) are expected to reduce stent-associated complications. This study aimed to assess the efficacy of DCB therapy and compare it with that of DES therapy in patients with ACS. Materials and Methods. In this single-center, retrospective, observational study, we examined all patients with ACS treated with DCB or DES between July 2014 and November 2020. Patients with left main trunk lesions were excluded. The primary outcome was a composite of major adverse cardiovascular events (MACE: cardiac death, myocardial infarction, and target lesion revascularization) at one year. Results. Three hundred and seventy-two patients were treated with DES, and 83 patients were treated with DCB. MACE occurred in 10 (12.0%) patients in the DCB group and in 50 (13.4%) patients in the DES group (). Conclusions. DCB is a valuable and effective therapy for patients with ACS. Moreover, DCB may become an alternative therapy for DES in patients with ACS.

中文翻译：

---

药物涂层球囊治疗急性冠脉综合征的疗效

背景。使用药物洗脱支架 (DES) 的经皮冠状动脉介入治疗是急性冠状动脉综合征 (ACS) 的常见治疗选择。然而，与支架相关的并发症，例如与双重抗血小板治疗相关的出血、支架内再狭窄、支架内血栓形成和新动脉粥样硬化仍然存在。药物涂层球囊 (DCB) 有望减少支架相关并发症。本研究旨在评估 DCB 治疗的疗效，并将其与 DES 治疗对 ACS 患者的疗效进行比较。材料和方法. 在这项单中心、回顾性、观察性研究中，我们检查了 2014 年 7 月至 2020 年 11 月期间接受 DCB 或 DES 治疗的所有 ACS 患者。排除了左主干病变的患者。主要结局是一年时主要不良心血管事件（MACE：心源性死亡、心肌梗死和靶病变血运重建）的复合。结果。372 名患者接受了 DES 治疗，83 名患者接受了 DCB 治疗。DCB 组 10 例 (12.0%) 患者和 DES 组 50 例 (13.4%) 患者发生 MACE（). 结论。DCB 是 ACS 患者有价值且有效的治疗方法。此外，DCB 可能成为 ACS 患者 DES 的替代疗法。